Benchmark Reiterates Speculative Buy Rating on Intensity Therapeutics, Inc. (INTS)

Benchmark analyst Robert Wasserman reiterated a Speculative Buy rating and $12.00 price target on Intensity Therapeutics, Inc. (NASDAQ: INTS).

The analyst commented, "Intensity Therapeutics reported financial results for their 1Q26 and provided an update on their clinical progress. Highlights during the first quarter included approval by the Swissmedic federal agency to resume enrollment in the Invincible4 study with INT230-6 in triple negative breast cancer (TNBC) following favorable efficacy and safety reported in a small patient sample size (5 out of 7), and a decision by the Company to resume enrollment in a limited number of US sites for the Invincible3 study using INT230-6 monotherapy in specific soft tissue sarcoma patients. In the first quarter Intensity posted a net loss of $2.4 million or ($0.96) per share as compared to a net loss of $3.3 million or ($5.51) per share in 1Q25. We are maintaining our Speculative Buy rating on INTS shares as the Company continues to make progress on its clinical programs."

For an analyst ratings summary and ratings history on Intensity Therapeutics, Inc. click here. For more ratings news on Intensity Therapeutics, Inc. click here.

Shares of Intensity Therapeutics, Inc. closed at $4.59 yesterday.

You May Also Be Interested In

• Ferguson Enterprises to Join S&P 500; ADI Global Distribution to Join S&P SmallCap 600
• General Dynamics wins $273 million in defense contracts
• Oceanfirst Financial (OCFC) Reports In-Line Q2 EPS